An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells
Payal Mittal,Rebecca Abblett,Joseph M Ryan,Adam T Hagymasi,Archibald Agyekum-Yamoah,Julia Svedova,Steven L Reiner,Marie-Clare St Rose,Matthew P Hanley,Anthony T Vella,Adam J Adler,Joseph M. Ryan,Adam T. Hagymasi,Steven L. Reiner,Marie-Clare St. Rose,Matthew P. Hanley,Anthony T. Vella,Adam J. Adler
DOI: https://doi.org/10.4049/jimmunol.1701039
2018-01-05
The Journal of Immunology
Abstract:Agonists to the TNF/TNFR costimulatory receptors CD134 (OX40) and CD137 (4-1BB) elicit antitumor immunity. Dual costimulation with anti-CD134 plus anti-CD137 is particularly potent because it programs cytotoxic potential in CD8<sup>+</sup> and CD4<sup>+</sup> T cells. Cytotoxicity in dual-costimulated CD4 T cells depends on the T-box transcription factor eomesodermin (Eomes), which we report is induced via a mechanism that does not rely on IL-2, in contrast to CD8<sup>+</sup> CTL, but rather depends on the CD8 T cell lineage commitment transcription factor Runx3, which supports Eomes expression in mature CD8<sup>+</sup> CTLs. Further, Eomes and Runx3 were indispensable for dual-costimulated CD4 T cells to mediate antitumor activity in an aggressive melanoma model. Runx3 is also known to be expressed in standard CD4 Th1 cells where it fosters IFN-γ expression; however, the CD4 T cell lineage commitment factor ThPOK represses transcription of <i>Eomes</i> and other CD8 lineage genes, such as <i>Cd8a</i> Hence, CD4 T cells can differentiate into Eomes<sup>+</sup> cytotoxic CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells by terminating ThPOK expression. In contrast, dual-costimulated CD4 T cells express Eomes, despite the continued expression of ThPOK and the absence of CD8α, indicating that <i>Eomes</i> is selectively released from ThPOK repression. Finally, although Eomes was induced by CD137 agonist, but not CD134 agonist, administered individually, CD137 agonist failed to induce CD134<sup>-/-</sup> CD4 T cells to express Eomes or Runx3, indicating that both costimulatory pathways are required for cytotoxic Th1 programming, even when only CD137 is intentionally engaged with a therapeutic agonist.
immunology